title: [Metabolic syndrome: which definition for what treatment(s)?].
abstract: Metabolic syndrome is asymptomatic and results from the increasing prevalence of obesity. Although several definitions exist and complicate its diagnosis, metabolic syndrome is characterized by the clustering of moderate troubles of glucose, lipid metabolism, body weight, hypertension and vascular inflammation ; the synergy between 3 of them triggers type 2 diabetes, atherosclerosis and associated clinical events. Whatever the age but particularly in adolescence, the prevalence of metabolic syndrome is high ; beyond lifestyle interventions, the available treatments address essentially a single risk factor and an unmet medical need persists. The reduction of cardiovascular events in secondary prevention has been demonstrated for some antidiabetic, hypolipidemic and antihypertensive agents but any difference in efficacy between populations with and without metabolic syndrome has yet to be established. The approval of metabolic syndrome as a specific therapeutic target would need the characterization of its pathogenic mechanism, a clearer guidance for definition and diagnosis, and the clinical proof of concept of a novel molecule displaying multifactorial impacts. Some new mechanistic approaches are discussed and may represent a breakthrough particularly if positive results of Field and Proactive clinical studies related to PPARs are disclosed soon.
authors.affiliation: Laboratoires Pierre Fabre, 17, avenue Jean Moulin, 81100 Castres, France. didier.junquero@pierre-fabre.com
authors.forename: Didier
authors.initials: D
authors.lastname: Junquero
authors.forename: Yves
authors.initials: Y
authors.lastname: Rival
mesh_terms: D006801:Humans; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000628:therapy*; D009626:Terminology as Topic